JP2025072482A5 - - Google Patents

Info

Publication number
JP2025072482A5
JP2025072482A5 JP2025016649A JP2025016649A JP2025072482A5 JP 2025072482 A5 JP2025072482 A5 JP 2025072482A5 JP 2025016649 A JP2025016649 A JP 2025016649A JP 2025016649 A JP2025016649 A JP 2025016649A JP 2025072482 A5 JP2025072482 A5 JP 2025072482A5
Authority
JP
Japan
Prior art keywords
poxvirus
nucleic acid
cancer
chimeric poxvirus
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025016649A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025072482A (ja
Filing date
Publication date
Priority claimed from PCT/US2017/046163 external-priority patent/WO2018031694A1/en
Application filed filed Critical
Publication of JP2025072482A publication Critical patent/JP2025072482A/ja
Publication of JP2025072482A5 publication Critical patent/JP2025072482A5/ja
Pending legal-status Critical Current

Links

JP2025016649A 2016-08-09 2025-02-04 キメラポックスウイルス組成物及びその使用 Pending JP2025072482A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662372408P 2016-08-09 2016-08-09
US62/372,408 2016-08-09
US201762519010P 2017-06-13 2017-06-13
US62/519,010 2017-06-13
PCT/US2017/046163 WO2018031694A1 (en) 2016-08-09 2017-08-09 Chimeric poxvirus compositions and uses thereof
JP2019507161A JP7023929B2 (ja) 2016-08-09 2017-08-09 キメラポックスウイルス組成物及びその使用
JP2022017693A JP7395628B2 (ja) 2016-08-09 2022-02-08 キメラポックスウイルス組成物及びその使用
JP2023200433A JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023200433A Division JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用

Publications (2)

Publication Number Publication Date
JP2025072482A JP2025072482A (ja) 2025-05-09
JP2025072482A5 true JP2025072482A5 (https=) 2025-09-09

Family

ID=61163330

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019507161A Active JP7023929B2 (ja) 2016-08-09 2017-08-09 キメラポックスウイルス組成物及びその使用
JP2022017693A Active JP7395628B2 (ja) 2016-08-09 2022-02-08 キメラポックスウイルス組成物及びその使用
JP2023200433A Active JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用
JP2025016649A Pending JP2025072482A (ja) 2016-08-09 2025-02-04 キメラポックスウイルス組成物及びその使用

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2019507161A Active JP7023929B2 (ja) 2016-08-09 2017-08-09 キメラポックスウイルス組成物及びその使用
JP2022017693A Active JP7395628B2 (ja) 2016-08-09 2022-02-08 キメラポックスウイルス組成物及びその使用
JP2023200433A Active JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用

Country Status (10)

Country Link
US (2) US12084687B2 (https=)
EP (1) EP3497209A4 (https=)
JP (4) JP7023929B2 (https=)
KR (3) KR20230113832A (https=)
CN (3) CN118853594A (https=)
AU (2) AU2017311380A1 (https=)
CA (1) CA3033512A1 (https=)
MX (1) MX2019001672A (https=)
RU (2) RU2757002C2 (https=)
WO (1) WO2018031694A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CN115300622A (zh) 2015-02-25 2022-11-08 纪念斯隆-凯特琳癌症中心 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合
CN107847534B (zh) 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
KR20180133395A (ko) 2016-02-25 2018-12-14 메모리얼 슬로안 케터링 캔서 센터 암 면역요법을 위한, 인간 flt3l 또는 gm-csf의 발현이 있거나 없으며 티미딘 키나제가 결실된 복제 가능 약독화 백시니아 바이러스
IL261321B2 (en) 2016-02-25 2023-12-01 Memorial Sloan Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
KR20230113832A (ko) * 2016-08-09 2023-08-01 시티 오브 호프 키메라 폭스바이러스 조성물 및 이의 용도
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
WO2018209315A1 (en) 2017-05-12 2018-11-15 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
WO2019033030A1 (en) * 2017-08-11 2019-02-14 City Of Hope ONCOLYTIC VIRUS EXPRESSING A CAR-T CELL TARGET AND USES THEREOF
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
CA3093093A1 (en) * 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors
WO2019213173A1 (en) * 2018-04-30 2019-11-07 City Of Hope Neural stem cell compositions including chimeric poxviruses for cancer treatment
MX2021003013A (es) 2018-09-15 2021-08-11 Memorial Sloan Kettering Cancer Center Poxvirus recombinantes para inmunoterapia contra cáncer.
CN113583977B (zh) * 2020-04-30 2025-06-06 杭州康万达医药科技有限公司 可受微小rna调控的分离的重组溶瘤痘病毒及其应用
GB2614309A (en) 2021-12-24 2023-07-05 Stratosvir Ltd Improved vaccinia virus vectors
WO2023213763A1 (en) * 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
US20260049291A1 (en) 2022-08-18 2026-02-19 Transgene Chimeric poxviruses
WO2024245722A2 (en) * 2023-05-26 2024-12-05 Probiogen Ag Rapid selection system for the generation of recombinant enveloped viruses
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof
CN120718864B (zh) * 2025-08-28 2025-11-28 山东农业大学 一种高度不成熟鸭坦布苏病毒及其培养方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT406376B (de) 1998-01-16 2000-04-25 Immuno Ag Chimäres poxvirus enthaltend eine retrovirale vektorkomponente
EP1268763A2 (en) 2000-03-28 2003-01-02 University Of Rochester Methods of producing a library and methods of selecting polynucleotides
CA2501168A1 (en) * 2002-11-25 2004-06-10 Bavarian Nordic A/S Recombinant poxvirus comprising at least two cowpox ati promoters
ATE420160T1 (de) * 2003-06-18 2009-01-15 Genelux Corp Modifizierte rekombinante vacciniaviren, verwendungen davon
EP2097517B1 (en) 2006-10-16 2014-06-04 Genelux Corporation Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody
HRP20150360T1 (hr) * 2007-11-19 2015-05-08 Transgene Sa Poksvirusni onkolitiäśki vektori
US20130071430A1 (en) * 2010-04-09 2013-03-21 The University Of Tokyo Microrna-controlled recombinant vaccinia virus and use thereof
ES2733211T3 (es) 2011-04-15 2019-11-28 Genelux Corp Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
JP2015520754A (ja) 2012-05-18 2015-07-23 オタゴ イノベーション リミテッド 創傷治癒のための組合せ治療および組成物
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
KR20230113832A (ko) * 2016-08-09 2023-08-01 시티 오브 호프 키메라 폭스바이러스 조성물 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2025072482A5 (https=)
JP2024026191A5 (https=)
RU2019106319A (ru) Композиции химерного поксвируса и их применение
JP2022065034A5 (https=)
JP2019524131A5 (https=)
CN101868474B (zh) 痘病毒溶瘤载体
CN101868546B (zh) 痘病毒溶瘤载体
Zhang et al. The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14. 5L inactivation
KR20170018450A (ko) 세포 치료제로서의 car-발현 nk-92 세포
AU2024200997A1 (en) Synthetic chimeric poxviruses
Brunetti et al. Complete Genomic Sequence and Comparative Analysis ofthe Tumorigenic Poxvirus Yaba Monkey TumorVirus
JP2021106576A (ja) 変異体腫瘍溶解性ワクシニアウイルスおよびその使用法
JP2021522825A5 (https=)
JP6657115B2 (ja) ポックスウイルス腫瘍細胞崩壊性ベクター
WO2020011754A1 (en) Chimeric vaccinia viruses
CN119530301B (zh) 一种治疗癌症的慢病毒及其制备方法和应用
EP2680867B1 (en) Enhanced tumor therapy by tumor stem cell targeted oncolytic viruses
EP3132038A1 (en) Adenoviral targeting, compositions and methods therefor
TW202014200A (zh) 包含合成嵌合牛痘病毒之幹細胞及其使用方法
WO2018101498A1 (ko) 유전자치료 벡터시스템 및 전구약물 유전자
WO2018067165A1 (en) Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer
KR100635447B1 (ko) 종양 특이적 자살유전자 발현 카세트 및 이를 포함하는아데노바이러스 발현 벡터
US20230340424A1 (en) Mutant orf viruses and uses thereof
Vasić Molecular targets and gene therapy of lung cancer